We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+20.43%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$869M
AUM Growth
-$37.3M
Cap. Flow
-$52.6M
Cap. Flow %
-6.05%
Top 10 Hldgs %
62.94%
Holding
54
New
3
Increased
9
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$18.8M
2
GERN icon
Geron
GERN
+$9.06M
3
ATXS
Astria Therapeutics
ATXS
+$7.02M
4
PCVX icon
Vaxcyte
PCVX
+$6.87M
5
CMPX icon
Compass Therapeutics
CMPX
+$6.21M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$43.7M
2
RLMD icon
Relmada Therapeutics
RLMD
+$26.4M
3
ASND icon
Ascendis Pharma A/S
ASND
+$15.1M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.67M
5
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.39M

Sector Composition

Rank Sector Weight
1 Healthcare 98.63%
2 Materials 1.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
1
Harmony Biosciences
HRMY
$2.07B
$144M 16.53%
2,606,247
-794,014
-23% -$43.7M
TERN
2
DELISTED
Terns Pharmaceuticals
TERN
$67.8M 7.8%
6,657,992
+758,620
+13% +$5.05M
VRDN icon
3
Viridian Therapeutics
VRDN
$2.15B
$49M 5.64%
1,678,207
+18,188
+1% +$419K
ALXO icon
4
ALX Oncology
ALXO
$268M
$47.6M 5.48%
4,220,048
– –
GERN icon
5
Geron
GERN
$930M
$46.7M 5.37%
19,282,834
+4,044,739
+27% +$9.06M
IMPL
6
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$43.3M 4.98%
2,884,789
– –
VTYX
7
DELISTED
Ventyx Biosciences
VTYX
$42.7M 4.92%
1,303,294
-52,567
-4% -$1.56M
SVA
8
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 4.4%
5,900,000
– –
ALLK
9
DELISTED
Allakos
ALLK
$34.7M 3.99%
4,120,134
– –
TARS icon
10
Tarsus Pharmaceuticals
TARS
$2.57B
$33.2M 3.82%
2,262,200
– –
PCVX icon
11
Vaxcyte
PCVX
$7.88B
$27.8M 3.2%
579,508
+175,000
+43% +$6.87M
ATXS
12
DELISTED
Astria Therapeutics
ATXS
$25M 2.88%
1,681,199
+681,199
+68% +$7.02M
COGT icon
13
Cogent Biosciences
COGT
$6.95B
$23.1M 2.66%
1,994,941
+111,000
+6% +$1.38M
KDNY
14
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$22.9M 2.63%
872,151
– –
VECT
15
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$20.2M 2.33%
+2,333,300
New +$18.8M
AVDL
16
DELISTED
Avadel Pharmaceuticals
AVDL
$19.7M 2.27%
2,754,095
-182,998
-6% -$1.28M
CMPX icon
17
Compass Therapeutics
CMPX
$367M
$17.9M 2.06%
3,557,630
+1,557,630
+78% +$6.21M
ACRS icon
18
Aclaris Therapeutics
ACRS
$744M
$14.2M 1.63%
898,631
– –
LEGN icon
19
Legend Biotech
LEGN
$3.68B
$12.2M 1.4%
244,375
– –
AMRS
20
DELISTED
Amyris Inc.
AMRS
$11.9M 1.37%
7,750,828
– –
ZLAB icon
21
Zai Lab
ZLAB
$2.1B
$10.4M 1.2%
338,721
+67,193
+25% +$2.12M
GTH
22
DELISTED
Genetron Holdings Limited ADS
GTH
$9.1M 1.05%
2,708,058
– –
BLU
23
DELISTED
BELLUS Health Inc.
BLU
$8.36M 0.96%
1,017,152
– –
TIL icon
24
Instil Bio
TIL
$49.4M
$7.87M 0.91%
624,339
– –
VERA icon
25
Vera Therapeutics
VERA
$2.39B
$7.75M 0.89%
400,666
-266,000
-40% -$4.82M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Vivo Capital held 54 positions worth $869M, down 4.1% from $906M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Vivo Capital withdrew a net $52.6M in Q4 2022, closing 6 positions and reducing 7 holdings. Its most notable exit was Relmada Therapeutics, an estimated $26.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Materials.

Against the trend, Vivo Capital opened a new position in VectivBio Holding AG Ordinary Shares worth $20.2M.

  • Vivo Capital's largest Q4 2022 buy was VectivBio Holding AG Ordinary Shares: 2,333,300 shares worth $20.2M.
  • Vivo Capital added most to Geron in Q4 2022, an estimated $9.06M increase.
  • Vivo Capital's biggest Q4 2022 reduction was Harmony Biosciences, cutting an estimated $43.7M.
  • Vivo Capital fully exited Relmada Therapeutics in Q4 2022, selling an estimated $26.4M.
  • Vivo Capital's ten largest holdings make up 63% of its $869M portfolio in Q4 2022.
  • Vivo Capital opened 3 new positions and closed 6 in Q4 2022.
  • Vivo Capital's portfolio value fell 4.1% quarter-over-quarter to $869M.

Based on Vivo Capital's 13F filing for Q4 2022, filed 13 Feb 2023.